Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Italy"

75 News Found

Azelis acquires Azienda Chimica e Farmaceutica to expand presence in Italy
Supply Chain | July 11, 2025

Azelis acquires Azienda Chimica e Farmaceutica to expand presence in Italy

Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders


UFlex’s FlexiTubes to showcase sustainable beauty packaging at COSMOPROF Italy 2025
Sustainability | March 20, 2025

UFlex’s FlexiTubes to showcase sustainable beauty packaging at COSMOPROF Italy 2025

FlexiTubes will showcase range of eco-friendly and innovative tube options


Thermo Fisher receives AIFA’s GMP approval for manufacturing facility of RNA-based products in Italy
News | January 22, 2024

Thermo Fisher receives AIFA’s GMP approval for manufacturing facility of RNA-based products in Italy

GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients


Lonza to acquire Exosomics service unit in Italy
Biotech | November 03, 2021

Lonza to acquire Exosomics service unit in Italy

Expertise in exosomes isolation and characterization will drive innovation in this field


IMCD and Friesland Campina Professional expand distribution agreement across EMEA
Supply Chain | July 11, 2025

IMCD and Friesland Campina Professional expand distribution agreement across EMEA

Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers


Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025
News | June 16, 2025

Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025

Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies


AstraZeneca’s fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia
News | June 07, 2025

AstraZeneca’s fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia

AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations


AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Diagnostic Center | May 03, 2025

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease


Zyuds Lifesciences receives USFDA approval for DMD treatment drug
Drug Approval | April 14, 2025

Zyuds Lifesciences receives USFDA approval for DMD treatment drug

Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older


Enhertu approved in EU in post-ET breast cancer
Drug Approval | April 04, 2025

Enhertu approved in EU in post-ET breast cancer

Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease